Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease
Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…Parkinson’s disease patients with onset in right side have a worse cognitive prognosis
Objective: The our intention was to investigate a dynamics of cognitive decline in patients with different side of onset parkinsonism in view of visual dysfunction…Illusional perception in Parkinson’s disease
Objective: To investigate (a) whether a susceptibility to illusional perceptions is intrinsic to Parkinson's disease even before the onset of hallucinations or cognitive impairment and…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study
Objective: To investigate the effect of levodopa on articulatory movement during Cantonese plosive production in individuals with Parkinson's disease (PD) by comparing kinematic parameters before…Supplement use in PD is associated with delayed initiation of dopaminergic therapy
Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)
Objective: To provide suggested guidance on how to select appropriate candidates for therapy with carbidopa/levodopa enteral suspension (CLES) based on published literature. Background: The introduction…
- « Previous Page
- 1
- …
- 3
- 4
- 5